Drug intelligence / Profile preview

metadoxine + silymarin

Development stage
Unknown
Lead developer
Aganit Pharma
Modality
Small Molecules
Administration
Oral
01

Overview

Dwenit Forte is a branded generic fixed-dose combination drug containing **metadoxine** and **silymarin**, marketed by **Aganit Pharma**. Metadoxine is a hepatoprotective agent that enhances the metabolism of alcohol by increasing the activity of acetaldehyde dehydrogenase and alcohol dehydrogenase, thereby reducing the duration of alcohol intoxication and the risk of liver damage. Silymarin, a flavonolignan complex extracted from milk thistle (*Silybum marianum*), acts as a potent antioxidant, scavenging free radicals and stabilizing the cell membranes of hepatocytes to prevent toxin entry and promote liver regeneration. This combination is primarily used for the treatment of alcoholic liver disease, fatty liver, and chronic inflammatory liver conditions.

Brand names
Dwenit Forte
Other names
metadoxine + silymarin
02

Targets

ADH (Alcohol dehydrogenase family)Pol I (RNA polymerase I)ALDH2 (Mitochondrial Aldehyde Dehydrogenase)ER (Estrogen receptor)

Beyond the preview

Go deeper on metadoxine + silymarin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on metadoxine + silymarin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call